Jade Biosciences announces first participant dosed in first-in-human Phase 1 clinical trial of JADE201, a novel half-life extended Afucosylated anti-BAFF receptor monoclonal antibody
[출처/시간] Briefing.com - 4:17 PM ET, 05/26/2026 SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc., (JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has been dosed in a first-in-human Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monocl
뉴스|admin|May 26, 2026
[출처/시간] Briefing.com - 4:17 PM ET, 05/26/2026
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc., (JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has been dosed in a first-in-human Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor designed to deplete B cells through a dual mechanism of action: enhanced antibody effector function and BAFF signal blockade. The Company expects interim FIH data in 2027.Click here for full release.
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.